论文部分内容阅读
目的分析肺癌患者在临床诊断中检验肿瘤标志物的结果和价值。方法以我院收治的80例肺癌患者作为试验组,同期良性肺病患者80例作为对照组。获取血清标本分别检验CA153、CA125的水平,观察检验结果异常率,并比较不同肺癌类型患者的检测结果。结果试验组患者CA153、CA125检验结果异常率(52.5%、81.3%)均高于对照组(11.3%、17.5%)。CA125水平鳞癌患者最高、小细胞癌患者最低、腺癌患者居中,差异有统计学意义(P<0.05)。单独检验CA153符合57例(71.3%),单独检验CA125符合66例(82.5%),联合检验符合68例(85.0%)。结论肺癌患者的CA153、CA125发生明显改变,联合检验能够提高诊断准确率,在患者的临床治疗、预后评价上具有较高的应用价值。
Objective To analyze the results and value of testing tumor markers in clinical diagnosis of lung cancer patients. Methods Eighty patients with lung cancer admitted to our hospital were selected as experimental group and 80 patients with benign lung disease as control group. Obtain serum samples to test the level of CA153 and CA125 respectively, observe the abnormal rate of test results, and compare the results of different types of lung cancer patients. Results The abnormal rates of CA153 and CA125 in the test group were higher than those in the control group (52.5% and 81.3%, 11.3% and 17.5%, respectively). Patients with CA125 had the highest level of squamous cell carcinoma, the lowest was small cell carcinoma, and the median of adenocarcinoma was statistically significant (P <0.05). 57 cases (71.3%) were examined by CA153 alone, 66 cases (82.5%) were tested by CA125 alone, and 68 cases (85.0%) were tested by joint test. Conclusion The CA153 and CA125 in patients with lung cancer have obvious changes. The combined test can improve the diagnostic accuracy and has high value in clinical treatment and prognosis evaluation.